Mass psychogenic illness after vaccination

 

 

PubMed.gov

Drug Saf. 2003;26(9):599-604.

Source

Department of Vaccines and Immunisation, World Health Organization, Geneva, Switzerland. ClementsCJ@telstra.com

Abstract

When vaccines are administered to groups, the physical reactions of the recipients may be similar, causing a form of mass reaction, the mechanism for which is the same as that for mass reactions from other causes. These phenomena have been categorised as mass psychogenic illness (MPI), and have been defined as the collective occurrence of a constellation of symptoms suggestive of organic illness but without an identified cause in a group of people with shared beliefs about the cause of the symptom(s). A review of the literature shows that such outbreaks have been reported in differing cultural and environmental settings including developing and industrialised countries, in the work place, on public transport, in schools, and the military. The perceived threats have been against agents such as food poisoning, fire and toxic gases. Whatever the place or perceived threat, the response seems to be similar. The symptoms generally included headache, dizziness, weakness, and loss of consciousness. Once under way, MPIs are not easy to stop. Incidents reported in the literature show that they can quickly gather momentum and can be amplified by the press who disseminate information rapidly, escalating the events. Management of such mass events can be extremely difficult. Should the public health official in charge continue to try and determine the cause, or should this person call off the entire investigation? It is suggested here that once vaccines are identified as a probable cause of the phenomenon, a dismissive approach may actually be harmful. Unless the spokesperson has already earned a high level of trust, the public are not likely to be convinced easily that nothing was wrong with the vaccine until it has been tested. An increased awareness of MPIs on the part of organisers of future mass vaccination campaigns seems appropriate. Immunisation managers should be aware that mass immunisation campaigns could generate such mass reactions. It is therefore essential that surveillance/reporting systems for reporting adverse events be improved before such campaigns. A mass campaign using a smallpox vaccine should be accompanied by a surveillance system capable of distinguishing between multiple cases of conventionally understood vaccine reactions and outbreaks of mass psychogenic illness.

PMID:
12814329
[PubMed - indexed for MEDLINE]

 

 

Read More…

Systemic lupus erythematosus following HPV immunization or infection?

Author: Soldevilla, H., Briones, S., Navarra, S.
Publication: Lupus
Volume: 21, Issue: 2, Pages: 158 to 161Date: Tuesday, January 10, 2012

Background and purpose: The link between autoimmunity and infectious agents has been strongly suggested by reports of lupus or lupus-like syndromes following immunization. This report describes three patients with either newly diagnosed systemic lupus erythematosus (SLE) or SLE flare, following vaccination for human papilloma virus (HPV).

Case 1: A 17-year-old female completed two doses of HPV vaccine uneventfully. Two months later, she developed arthralgias with pruritic rashes on both lower extremities, later accompanied by livedo reticularis, bipedal edema with proteinuria, anemia, leucopenia, hypocomplementemia and high titers of anti-nuclear antibody (ANA) and anti-double-stranded DNA (anti-dsDNA). Kidney biopsy showed International Society of Nephrology/Renal Pathology Society Class III lupus nephritis. She was started on high dose steroids followed by pulse cyclophosphamide therapy protocol for lupus nephritis, and subsequently went into remission.

Case 2: A 45-year-old housewife, previously managed for 11 years as having rheumatoid arthritis, had been in clinical remission for a year when she received two doses of HPV immunization. Four months later, she developed fever accompanied by arthritis, malar rash, oral ulcers, recurrent ascites with intestinal pseudo-obstruction, and behavioral changes. Cranial MRI showed vasculitic lesions on the frontal and parietal lobes. Laboratory tests showed anemia with leucopenia, hypocomplementemia, proteinuria, ANA positive at 1:320, and antibodies against dsDNA, Ro/SSA, La/SSB and histone. She improved following pulse methylprednisolone with subsequent oral prednisone combined with hydroxychloroquine.

Case 3: A 58-year-old housewife diagnosed with SLE had been in clinical remission for 8 years when she received two doses of HPV immunization. Three months later, she was admitted to emergency because of a 1-week history of fever, malar rash, easy fatigability, cervical lymph nodes, gross hematuria and pallor. Laboratory exams showed severe anemia, thrombocytopenia, active urine sediments, and hypocomplementemia. Despite pulse steroid therapy, blood transfusions, intravenous immunoglobulin and aggressive resuscitative measures, she expired a day after hospital admission.

Summary: These cases narrate instances of the onset or exacerbation of lupus following HPV immunization suggesting adjuvant-induced autoimmunity. On the other hand, there are reports of higher incidence of HPV infection in SLE, with the infection per se possibly contributing to disease activity. Thus, the benefit of HPV immunization may still outweigh the risk among these individuals.

Access entire article via this link.

Autoimmune encephalitis: a case series and comprehensive review of the literature

Wingfield TMcHugh CVas ARichardson AWilkins EBonington AVarma A.

Source

The Monsall Unit, Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital, Manchester, UK. tomwingfield@hotmail.co.uk

Abstract

Encephalitic syndromes are a common medical emergency. The importance of early diagnosis and appropriate treatment is paramount. If initial investigations for infectious agents prove negative, other diagnoses must be considered promptly. Autoimmune encephalitides are being increasingly recognized as important (and potentially reversible) non-infectious causes of an encephalitic syndrome. We describe four patients with autoimmune encephalitis–3 auto-antibody positive, 1 auto-antibody negative–treated during the last 18 months. A comprehensive review of the literature in this expanding area will be of interest to the infectious diseases, general medical and neurology community.

PMID:  21784780 [PubMed - in process]

Access entire paper via this link.

Human papillomavirus (HPV) vaccine policy and evidence-based medicine: Are they at odds?

Ann Med. 2011 Dec 22. [Epub ahead of print]

Tomljenovic LShaw CA.

Source

Neural Dynamics Research Group, Department of Ophthalmology and Visual Sciences, University of British Columbia , 828 W. 10th Ave, Vancouver, BC, V5Z 1L8 , Canada.

Abstract

All drugs are associated with some risks of adverse reactions. Because vaccines represent a special category of drugs, generally given to healthy individuals, uncertain benefits mean that only a small level of risk for adverse reactions is acceptable. Furthermore, medical ethics demand that vaccination should be carried out with the participant’s full and informed consent. This necessitates an objective disclosure of the known or foreseeable vaccination benefits and risks. The way in which HPV vaccines are often promoted to women indicates that such disclosure is not always given from the basis of the best available knowledge. For example, while the world’s leading medical authorities state that HPV vaccines are an important cervical cancer prevention tool, clinical trials show no evidence that HPV vaccination can protect against cervical cancer. Similarly, contrary to claims that cervical cancer is the second most common cancer in women worldwide, existing data show that this only applies to developing countries. In the Western world cervical cancer is a rare disease with mortality rates that are several times lower than the rate of reported serious adverse reactions (including deaths) from HPV vaccination. Future vaccination policies should adhere more rigorously to evidence-based medicine and ethical guidelines for informed consent.

PMID:  22188159 [PubMed - as supplied by publisher]
Access entire paper when available via this link.

Adverse Events following 12 and 18 Month Vaccinations: a Population-Based, Self-Controlled Case Series Analysis

By Kumanan Wilson1,2,3,4*, Steven Hawken2, Jeffrey C. Kwong5, Shelley Deeks6, Natasha S. Crowcroft6, Carl Van Walraven1,2,3, Beth K. Potter2,3, Pranesh Chakraborty4,8,Jennifer Keelan7, Michael Pluscauskas4, Doug Manuel2,3,9

Abstract:

Background

Live vaccines have distinct safety profiles, potentially causing systemic reactions one to 2 weeks after administration. In the province of Ontario, Canada, live MMR vaccine is currently recommended at age 12 months and 18 months.

Methods

Using the self-controlled case series design we examined 271,495 12 month vaccinations and 184,312 18 month vaccinations to examine the relative incidence of the composite endpoint of emergency room visits or hospital admissions in consecutive one day intervals following vaccination. These were compared to a control period 20 to 28 days later. In a post-hoc analysis we examined the reasons for emergency room visits and the average acuity score at presentation for children during the at-risk period following the 12 month vaccine.

Results

Four to 12 days post 12 month vaccination, children had a 1.33 (1.29–1.38) increased relative incidence of the combined endpoint compared to the control period, or at least one event during the risk interval for every 168 children vaccinated. Ten to 12 days post 18 month vaccination, the relative incidence was 1.25 (95%, 1.17–1.33) which represented at least one excess event for every 730 children vaccinated. The primary reason for increased events was statistically significant elevations in emergency room visits following all vaccinations. There were non-significant increases in hospital admissions. There were an additional 20 febrile seizures for every 100,000 vaccinated at 12 months.

Conclusions

There are significantly elevated risks of primarily emergency room visits approximately one to two weeks following 12 and 18 month vaccination. Future studies should examine whether these events could be predicted or prevented.

Access entire article here.

Citation: Wilson K, Hawken S, Kwong JC, Deeks S, Crowcroft NS, et al. (2011) Adverse Events following 12 and 18 Month Vaccinations: a Population-Based, Self-Controlled Case Series Analysis. PLoS ONE 6(12): e27897. doi:10.1371/journal.pone.0027897

Editor: Shabir Ahmed Madhi, University of Witwatersrand, South Africa

Received: August 5, 2011; Accepted: October 27, 2011; Published: December 12, 2011

Copyright: © 2011 Wilson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by the Canadian Foundation for Innovation, the Population Health Improvement Research Network (PHIRN), and by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES, Ontario MOHLTC or PHIRN is intended or should be inferred. Dr. Wilson holds the Canada Research Chair in Public Health Policy. Dr. Manuel holds the CIHR Chair in Applied Public Health. Dr. Kwong and Professor Keelan are supported by a Career Scientist award from the Ontario Ministry of Health and Long-Term Care. Dr Kwong is also supported by a Clinician Scientist award from the Department of Family and Community Medicine, University of Toronto. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

 

Assuring the Quality, Safety, and Efficacy of DNA Vaccines

Robertson JSGriffiths E

Source

National Institute for Biological Standards and Control, Herts, UK.

Methods Mol Med. 2006;127:363-74.

Abstract

Scientists in academia whose research is aimed at the development of a novel vaccine or approach to vaccination may not always be fully aware of the regulatory process by which a candidate vaccine becomes a licensed product. It is useful for such scientists to be aware of these processes, as the development of a novel vaccine could be problematic as a result of the starting material often being developed in a research laboratory under ill-defined conditions. This chapter examines the regulatory process with respect to the development of a DNA vaccine. DNA vaccines present unusual safety considerations which must be addressed during nonclinical safety studies, including adverse immunopathology, genotoxicity through integration into a vaccinee’s chromosomes and the potential for the formation of anti-DNA antibodies.

Access entire article via this link.

Human papillomavirus DNA detected in peripheral blood samples from healthy Australian male blood donors

J Med Virol. 2009 Oct;81(10):1792-6

Chen AC, Keleher A, Kedda MA, Spurdle AB, McMillan NA, Antonsson A.

The University of Queensland, Diamantina Institute for Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, Woolloongabba, Brisbane, QLD, Australia.

Abstract

Recent studies have shown that human papillomavirus (HPV) DNA can be found in circulating blood, including peripheral blood mononuclear cells (PBMCs), sera, plasma, and arterial cord blood. In light of these findings, DNA extracted from PBMCs from healthy blood donors were examined in order to determine how common HPV DNA is in blood of healthy individuals. Blood samples were collected from 180 healthy male blood donors (18-76 years old) through the Australian Red Cross Blood Services. Genomic DNA was extracted and specimens were tested for HPV DNA by PCR using a broad range primer pair. Positive samples were HPV-type determined by cloning and sequencing. HPV DNA was found in 8.3% (15/180) of the blood donors. A wide variety of different HPV types were isolated from the PBMCs; belonging to the cutaneous beta and gamma papillomavirus genera and mucosal alpha papillomaviruses. High-risk HPV types that are linked to cancer development were detected in 1.7% (3/180) of the PBMCs. Blood was also collected from a healthy HPV-positive 44-year-old male on four different occasions in order to determine which blood cell fractions harbor HPV. PBMCs treated with trypsin were negative for HPV, while non-trypsinized PBMCs were HPV-positive. This suggests that the HPV in blood is attached to the outside of blood cells via a protein-containing moiety. HPV was also isolated in the B cells, dendritic cells, NK cells, and neutrophils. To conclude, HPV present in PBMCs could represent a reservoir of virus and a potential new route of transmission.

Access entire paper here.

Could Human Papillomaviruses Be Spread through Blood?

J Clin Microbiol. 2005 November; 43(11): 5428–5434
doi: 10.1128/JCM.43.11.5428-5434.2005

Sohrab Bodaghi,1 Lauren V. Wood,1 Gregg Roby,1 Celia Ryder,1 Seth M. Steinberg,2 and Zhi-Ming Zheng1*

HIV and AIDS Malignancy Branch,1 Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland2

*Corresponding author. Mailing address: HIV and AIDS Malignancy Branch, Center for Cancer Research, NCI/NIH, 10 Center Dr., Rm. 10 S255, MSC-1868, Bethesda, MD 20892-1868. Phone: (301) 594-1382. Fax: (301) 480-8250. E-mail: zhengt@exchange.nih.gov.

Abstract:

The human papillomaviruses (HPVs) are epitheliotropic viruses that require the environment of a differentiating squamous epithelium for their life cycle. HPV infection through abrasion of the skin or sexual intercourse causes benign warts and sometimes cancer. HPV DNA detected in the blood has been interpreted as having originated from metastasized cancer cells. The present study examined HPV DNA in banked, frozen peripheral blood mononuclear cells (PBMCs) from 57 U.S. human immunodeficiency virus (HIV)-infected pediatric patients collected between 1987 and 1996 and in fresh PBMCs from 19 healthy blood donors collected in 2002 to 2003. Eight patients and three blood donors were positive mostly for two subgroups of the HPV type 16 genome. The HPV genome detected in all 11 PBMC samples existed as an episomal form, albeit at a low DNA copy number. Among the eight patients, seven acquired HIV from transfusion (three associated with hemophilia) and one acquired HIV through vertical transmission; this patient also had received a transfusion before sampling. Our data suggest that PBMCs may be HPV carriers and might spread the virus through blood.

Access the entire article here.

Dangers of HPV Vaccine Production in Plants, Microbes, and Viruses

Prof. Joe Cummins and Dr. Mae-Wan Ho

ISIS Report 07/01/09

Widespread releases of hazardous transgenes and vaccines have the potential to create viruses more deadly than the ones the vaccines protect against.

Human papilloma virus (HPV) vaccines are already commercialised and promoted worldwide in a bid to protect young girls and women from cervical cancer [1, 2] (Recombinant Cervical Cancer VaccinesSiS 29; The HPV Vaccine ControversySiS 41), while there is still major uncertainty over their efficacy and safety, especially in the long term. One obstacle to the adoption of the vaccines by developing countries is that the two available are very costly. There appears to have been a rush to create cheap oral HPV vaccines in transgenic plants, microbes and viruses that do not require refrigeration and can be distributed relatively inexpensively, but would involve widespread releases of hazardous transgenes and products into the open environment. Some of these are near commercialization, and regulators must be warned against the approval of such production methods unless and until strict containment and safeguards are put in place.

HPV Vaccines in Crop Plants

The main concern over the vaccines produced in crop plants is that transgenes from tests sites or production farms can readily spread by pollen or by mechanical dispersal of seeds.  Debris from transgenic crops can also spread transgenes and vaccine proteins through contaminating surface and groundwater. Debris in the form of dust in the air can impact on the respiratory mucosa directly, with the potential of triggering acute and delayed immune reactions in humans and animals exposed. HPV vaccines have already been associated with various adverse acute immune reactions some of which resulted in death [2]. People subject to persistent exposure to the crop vaccine are likely to develop oral tolerance rendering them susceptible to virus infection [3] (Pharm Crops for Vaccines and Therapeutic AntibodiesSiS 24)..

Read more….

 

The pathogenesis of Human Papillomavirus (HPV) in the development of cervical cancer: are HPV vaccines a safe and effective management strategy?

By Judy Wilyman, MSc

Abstract
Human Papillomavirus (HPV) infection has been linked with cervical cancer. Some medical professionals see it as the determining causal agent and therefore promote vaccination as an effective prevention strategy. However, the biological plausibility of a causal theory requires that the incidence of the causal agent varies with the incidence and mortality of the disease. Yet the incidence and mortality of cervical cancer do not vary with the incidence of infection with HPV strains 16 and 18; the strains covered by the HPV vaccine. Though HPV infection is a necessary precursor to most cervical cancer, most high-risk HPV infections (with one of 15 or more high–risk strains) do not progress to cervical cancer and HPV infection with any strain is not sufficient on its own to induce cervical cancer. This evidence supports the conclusion that environmental and lifestyle factors are a determining cause in conjunction with HPV in the progression to cervical cancer.

Clinical trials for the HPV vaccine did not attempt to observe the vaccine preventing any cervical cancer. Instead the trials looked for pre-cancerous lesions in women 16 – 26 years of age. This was an inadequate surrogate for cervical cancer because studies show that most lesions in this demographic clear quickly without requiring treatment. Preventing infection from HPV strains 16 and 18 also assumes these women will not get cervical cancer from infection with one of the many other high risk strains that are prevalent. Therefore the decision to use an HPV vaccine to prevent cervical cancer was based upon circumstantial evidence: assumptions. HPV vaccines have been promoted to women on selective information. This vaccine is an HPV vaccine not a cervical cancer vaccine. There is inconclusive evidence it will reduce any cervical cancer and the long –term risks of using this vaccine have not been determined.

Read the entire paper here.

Pharma Videos

cervarix 2

Vaccine Groups

center-for-personal-rights-logo

SaneVax Press Releases

SANE Vax logo